Screening of traditional Chinese medicine monomers as ribonucleotide reductase M2 inhibitors for tumor treatment

doi:10.12998/wjcc.v10.i31.11299

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 31

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3247)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

149

WORD

HTML

1786

Figures (1-5)

395

Tables (1-3)

200

Sum=2568

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

243

Download

436

Sum=679

Nov 6, 2022 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical and Translational Research

World J Clin Cases. Nov 6, 2022; 10(31): 11299-11312
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11299

Full Size Figure Download Figure

Figure 4 Berberine/ursolic acid/gambogic acid/cinobufagin and RRM2 protein have binding energy. A: The molecular docking diagram of berberine with ribonucleotide reductase M2 (RRM2) protein; B: The molecular docking diagram of ursolic acid with RRM2 protein; C: The molecular docking diagram of gambogic acid with RRM2 protein; D: The molecular docking diagram of cinobufagin with RRM2 protein.

Citation: Qin YY, Feng S, Zhang XD, Peng B. Screening of traditional Chinese medicine monomers as ribonucleotide reductase M2 inhibitors for tumor treatment. World J Clin Cases 2022; 10(31): 11299-11312
URL: https://www.wjgnet.com/2307-8960/full/v10/i31/11299.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i31.11299